Korean J Anesthesiol.  1994 May;27(5):428-448. 10.4097/kjae.1994.27.5.428.

The effects of nalbuphine and fentanyl on experimental spinal cord injuries

Affiliations
  • 1Department of Anesthesiology, Chungnam National University College of Medicine, Daejon, Korea.

Abstract

Opiate receptor agonists (especially dynorphin - a kappa receptor agonist) have found to increase in the injuried segment of spinal cord. It is known to cause spinal cord damage when injected intrathecally. Nalbuphine is a kappa opiate receptor agonist/partial mu antagonist, and fentanyl is selective mu receptor agonist. To determine the effect of nalbuphine and fentanyl on experimental spinal cord injuries of Spague-Dawley rats (N=125): 1) I determinded the MAC (or ED50) values of enflurane, fentanyl, nalbuphine-enflurane in 65% N2O; 2) produced spinal cord injury model by different epidural ballooning time in the control (enflurane) gmup ; 3) produced spinal cord injuries in the experimental (fentanyl, nalbuphine-enflurane) group. The results were as follows ; 1) The MAC value of enflurane was 1.16+/-0.05%, and the ED50 values of fentanyl were 26.8, 36.2, 39.7, 44.7 ug/kg after 15, 30, 45, 60 min of injection, respectively. Also the MAC values of enflurane with 20 mg/kg nalbuphine were 1.08, 0.99% after 60, 90 min of injection, respectively. 2) We produced the graded spinal cord injuries by different epidural ballooning time. 3) The total neurological scores of fentanyl experimental group were significantly higher than control group on the 10th, 14th, and 21st postinjury day.

Keyword

Spinal cord injury; Nalbuphine; Fentanyl; Kappa opiate reeeptor

MeSH Terms

Animals
Dynorphins
Enflurane
Fentanyl*
Nalbuphine*
Rats
Receptors, Opioid
Receptors, Opioid, kappa
Receptors, Opioid, mu
Spinal Cord Injuries*
Spinal Cord*
Dynorphins
Enflurane
Fentanyl
Nalbuphine
Receptors, Opioid
Receptors, Opioid, kappa
Receptors, Opioid, mu
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr